Tuberculosis Clinical Trial
Official title:
Open-label Prospective Noncomparative Study of Safety, Tolerability and Pharmacokinetics of PBTZ169 After Single and Multiple Fasting Oral Administration in Increasing Doses in Healthy Volunteers
Verified date | March 2020 |
Source | Nearmedic Plus LLC |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Open-label prospective non-comparative safety, tolerability and pharmacokinetics ascending dose randomized cohort study of PBTZ169 (capsules 40 mg) in fasted healthy volunteers after single and multiple oral administration
Status | Completed |
Enrollment | 40 |
Est. completion date | November 2016 |
Est. primary completion date | September 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 45 Years |
Eligibility |
Inclusion Criteria: 1. Written informed consent received from a volunteer. 2. Man aged 18 to 45 years old, inclusive. 3. Body mass index of 18.5-25 kg/m2. 4. Verified diagnosis: "healthy" according to data of standard clinical, laboratory and instrumental examination methods performed at screening: - Absence of deviations of physical examination parameters and vital signs (systolic blood pressure - 100-129 mm Hg, inclusive; diastolic blood pressure - 70-89 mm Hg, inclusive; heart rate - 60-80 bpm, inclusive); - Absence of deviations of laboratory parameters (complete blood count, blood biochemistry, urinalysis and tests for HIV, HBV, HCV, syphilis); - Normal parameters of 12-lead ECG; - Normal results of photofluorographic or X-ray examination (the results received maximum 6 months before screening can be used). 5. Ability, according to investigators opinion, to comply with all requirements of the protocol. 6. Agreement to use double contraception method during the study participation and for 3 months after the test drug administration - combination of male condom with not less than one of the following methods: - female partner using hormonal contraception; - using aerosols, creams, suppositories and other agents containing spermicides; - female partner using intrauterine device Exclusion Criteria: 1. Aggravated allergic history, including presence of at least one episode of drug allergy. 2. Chronic diseases of cardiovascular, bronchopulmonary, neuroendocrine systems, ENT and gastrointestinal, hepatic, renal, blood and cutaneous diseases. 3. Chronic diseases of eyes except for mild to moderate myopia, hypermetropia and astigmatism. 4. Gastrointestinal surgeries (except for appendectomy performed not less than 1 year before screening). 5. Acute infections within less than 4 weeks before screening. 6. Regular drug administration within less than 4 weeks before screening. 7. Regular administration or application (including topical) of hormonal drugs for more than 1 week within less than 45 days before the screening. 8. Administration of drugs exerting evident effects on hemodynamics, hepatic function, etc. (barbiturates, omeprazole, cimetidine, etc.) within less than 45 days before the screening. 9. Positive tests for narcotic and psychotropic agents. 10. Donation (450 mL of blood or plasma) within less than 3 months before the screening. 11. Intake of more than 10 U of alcohol per week (1 unit of alcohol is equivalent to 500 mL of beer, 200 mL of vine or 50 mL of strong alcoholic drink) or historical data on alcoholism, narcomania, drug abuse. 12. Mental illnesses. 13. Smoking within half a year before the screening. 14. Previous participation in this clinical study and withdrawal from it due to any reason. 15. Participation in other clinical studies of drugs within less than 6 months before the screening. 16. Planned conception or sperm donation during the study after the test drug administration or during 3 months after the date of drug administration. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Nearmedic Plus LLC | OCT LLC |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of Drug-related Adverse Events [Safety and Tolerability] | The frequency of adverse events for which a relationship to the test drug PBTZ169 was noted | 14±1 days after the drug administration (up to last visit time point) | |
Secondary | Peak Plasma Concentration (?max) of PBTZ169 | Up to 72 hours after the last drug administration: Single dosing (Cohorts 1-5): up to Day 4 (72 h after the dosing (Day 1)) Multiple dosing (Cohorts 6. 7): up to Day 17 (72 h after the last (14th) dosing) |
Up to 72 hours after the last drug administration | |
Secondary | Time to Reach Maximum Concentration (Tmax) of PBTZ169 | Single dosing (Cohorts 1-5): data for the dosing day (Day 1). Multiple dosing (Cohorts 6, 7): data for days 1 (1st dose), 7 and 14 (last dose) | Up to 72 hours after the last drug administration | |
Secondary | Area Under the Concentration-time Curve (AUC0-8) | In the time interval from 0 to infinity | Up to 72 hours after the last drug administration | |
Secondary | Plasma Half-life Time (T1/2) of PBTZ169 | Single dosing (Cohorts 1-5): data for the dosing day (Day 1). Multiple dosing (Cohorts 6, 7): data for days 1 (1st dose), 7 and 14 (last dose) | Up to 72 hours after the last drug administration | |
Secondary | Mean Plasma Retention Time (MRT) of PBTZ169 | Up to 72 hours after the last drug administration | ||
Secondary | Total (Plasma) Clearance (Cl) of PBTZ169 | The Cl parameter was calculated using the following formulas: for Day 1: Cl=D/AUCinf; for Days 7 and 14: Clss=D/AUCt | Up to 72 hours after the last drug administration | |
Secondary | Volume of Distribution (Vd) of PBTZ169 | Up to 72 hours after the last drug administration | ||
Secondary | Elimination Constant (Kel) of PBTZ169 | Data for doses 320 mg (Cohorts 4 and 6, total 11 volunters) & 640 mg (Cohorts 5 and 7, total 11 volunters) were combined | Up to 72 hours after the last drug administration | |
Secondary | Renal Clearance (Clren) of PBTZ169 | The renal clearance was calculated using values of the cumulative excretion in urine (from zero to 24 hours) and the area under the pharmacokinetic curve (from zero to 24 hours) (the ratio of the cumulative excretion to AUC0-24) | Up to 24 hours after the drug administration | |
Secondary | Peak Steady State Plasma Concentration (Cmax,ss) of PBTZ169 | For cohorts 6 and 7 (multiple administration) only | Up to 72 hours after the last drug administration | |
Secondary | Time to Reach Maximum Steady State Concentration (Tmax,ss) of PBTZ169 | For cohorts 6 and 7 (multiple administration) only | Up to 72 hours after the last drug administration | |
Secondary | Area Under the Plasma Concentration Versus Time Curve in Steady State (AUCss) of PBTZ169 | For cohorts 6 and 7 (multiple administration) only | Up to 72 hours after the last drug administration | |
Secondary | Volume of Steady State Distribution (Vd,ss) of PBTZ169 | For cohorts 6 and 7 (multiple administration) only | Up to 72 hours after the last drug administration | |
Secondary | Area Under the Concentration-time Curve (AUC0-t) | The area under the concentration-time curve from 0 to last blood sampling | Up to 72 hours after the last drug administration | |
Secondary | AUC0-t/AUC0-8 | AUC0-t/AUC0-8 ratio | Up to 72 hours after the last drug administration |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05738681 -
Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial
|
Phase 2/Phase 3 | |
Recruiting |
NCT05526885 -
Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa
|
N/A | |
Completed |
NCT04369326 -
Community Initiated Preventive Therapy for TB
|
N/A | |
Recruiting |
NCT04568967 -
TB-CAPT EXULTANT - HIV
|
N/A | |
Completed |
NCT02337270 -
Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol
|
Phase 1 | |
Not yet recruiting |
NCT06253715 -
Shortened Regimen for Drug-susceptible TB in Children
|
Phase 3 | |
Recruiting |
NCT04271397 -
Immunological Biomarkers in Tuberculosis Management
|
N/A | |
Withdrawn |
NCT03639038 -
Tuberculosis Diagnosis by Flow Cytometry
|
||
Completed |
NCT03199313 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid
|
Phase 1 | |
Recruiting |
NCT04975178 -
Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
|
Phase 3 | |
Completed |
NCT04463680 -
Rifampin and the Contraceptive Implant
|
Phase 4 | |
Completed |
NCT03973970 -
Assessing the Ability of the T-SPOT®.TB Test (IQ)
|
||
Recruiting |
NCT04230395 -
Alcohol Reduction Among People With TB and HIV in India
|
N/A | |
Completed |
NCT04874948 -
Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
|
Phase 1 | |
Active, not recruiting |
NCT02906007 -
Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05917210 -
Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda
|
N/A | |
Not yet recruiting |
NCT05845112 -
Start Taking Action For TB Diagnosis
|
||
Not yet recruiting |
NCT06017843 -
Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding
|
N/A | |
Active, not recruiting |
NCT02715271 -
Study of TB Lesions Obtained in Therapeutical Surgery
|
||
Completed |
NCT02781909 -
Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis
|
Phase 2 |